Health Care & Life Sciences » Biotechnology | Seattle Genetics Inc.

Seattle Genetics Inc.

Seattle Genetics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
158.79 M
Public Float
106.67 M
Seattle Genetics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.78
Market Cap
$11.14 B
Shares Outstanding
161.32 M
Public Float
158.22 M

Profile

Address
21823 30th Drive SE
Bothell Washington 98021
United States
Employees -
Website http://www.seattlegenetics.com
Updated 07/08/2019
Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.

Financials

View All

Clay B. Siegall
Chairman, President & Chief Executive Officer
Alpna Seth
Independent Director